Archive | May, 2016

Proteus Digital Health Misses The FDA Mark And Maybe More




OK, so the FDA smacked down every investor’s poster child for the promise of ingestibles and digital health.  Yes, last week, the FDA declined to approve the output of the collaboration between Proteus Digital Health and Otsuka Pharmaceutical Development and Commercialization, which would enable patients, payors and providers to track the use (adherence) of Otsuka’s antipsychotic medication Abilify. […]




Continue Reading